- Home
- SLAI vs LIXT Comparison
SLAI vs LIXT Comparison
Compare SLAI & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SLAI
- LIXT
- Stock Information
- Founded
- SLAI 2001
- LIXT 2005
- Country
- SLAI United States
- LIXT United States
- Employees
- SLAI N/A
- LIXT N/A
- Industry
- SLAI EDP Services
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- SLAI Technology
- LIXT Health Care
- Exchange
- SLAI Nasdaq
- LIXT Nasdaq
- Market Cap
- SLAI 23.1M
- LIXT 20.5M
- IPO Year
- SLAI N/A
- LIXT N/A
- Fundamental
- Price
- SLAI $2.38
- LIXT $4.15
- Analyst Decision
- SLAI
- LIXT
- Analyst Count
- SLAI 0
- LIXT 0
- Target Price
- SLAI N/A
- LIXT N/A
- AVG Volume (30 Days)
- SLAI 390.9K
- LIXT 134.1K
- Earning Date
- SLAI 11-19-2025
- LIXT 11-11-2025
- Dividend Yield
- SLAI N/A
- LIXT N/A
- EPS Growth
- SLAI N/A
- LIXT N/A
- EPS
- SLAI N/A
- LIXT N/A
- Revenue
- SLAI $24,576,000.00
- LIXT N/A
- Revenue This Year
- SLAI N/A
- LIXT N/A
- Revenue Next Year
- SLAI N/A
- LIXT N/A
- P/E Ratio
- SLAI N/A
- LIXT N/A
- Revenue Growth
- SLAI N/A
- LIXT N/A
- 52 Week Low
- SLAI $1.22
- LIXT $0.64
- 52 Week High
- SLAI $8.07
- LIXT $6.26
- Technical
- Relative Strength Index (RSI)
- SLAI N/A
- LIXT 40.70
- Support Level
- SLAI N/A
- LIXT $4.18
- Resistance Level
- SLAI N/A
- LIXT $4.56
- Average True Range (ATR)
- SLAI 0.00
- LIXT 0.41
- MACD
- SLAI 0.00
- LIXT -0.07
- Stochastic Oscillator
- SLAI 0.00
- LIXT 20.20
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.